Evidence map›Paper›PMID 41235365›Full record

ReviewMaterials today. Bio2025

The drug discovery and therapeutic nano-strategies targeting cellular senescence.

Yumei Wang, Mingqi Liu, Xinzhao Chen, Song Wang, Jiatong Li, Yuman Sun, Xuting Zheng, Jianxiang Zhang, Heran Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yumei WangDepartment of Pharmaceutics, College of Pharmacy, Army Medical University, Chongqing, 400038, China.
Mingqi LiuWomen's Hospital, Zhejiang University School of Medicine, Hangzhou, 310006, China.
Xinzhao ChenDepartment of Histology and Embryology, College of Basic Medical Science, China Medical University, Shenyang, 110122, China.
Song WangDepartment of Pharmaceutics, College of Pharmacy, Army Medical University, Chongqing, 400038, China.
Jiatong LiSchool of Pharmacy, China Medical University, Shenyang, 110122, China.
Yuman SunSchool of Pharmacy, China Medical University, Shenyang, 110122, China.
Xuting ZhengDepartment of Infectious Disease, The First Hospital of China Medical University, Shenyang, 110001, China.
Jianxiang ZhangDepartment of Pharmaceutics, College of Pharmacy, Army Medical University, Chongqing, 400038, China.
Heran LiSchool of Pharmacy, China Medical University, Shenyang, 110122, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular senescence is a primary driver of aging, where damaged or senescent cells (SnCs) continuously accumulate in the body, altering the local tissue environment and causing various pathologies in different organs or tissues, offering brand-new diagnostic and therapeutic possibilities for aging-related disease. This review begins by discussing the multiple molecular mechanisms of cellular senescence. We mainly focus on the therapeutic strategies and their clinical applications targeting cellular senescence, where senolytic and senomorphic drugs are currently two main categories of anti-aging therapies. Besides, nicotinamide adenine dinucleotide (NAD

Indexed as

Aging-related diseaseNanotechnology-based drug delivery systemSenescent cellsSenotherapySWOT analysis

Identifiers

PMID41235365
PMCPMC12605296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.